{"id":19398,"date":"2020-08-28T08:38:43","date_gmt":"2020-08-28T12:38:43","guid":{"rendered":"https:\/\/www.benefitscanada.com\/news\/plan-sponsor-week-using-analytics-to-monitor-non-adherence-disease-states-149291"},"modified":"2020-08-28T08:38:43","modified_gmt":"2020-08-28T12:38:43","slug":"plan-sponsor-week-using-analytics-to-monitor-non-adherence-disease-states","status":"publish","type":"post","link":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/2020\/08\/28\/plan-sponsor-week-using-analytics-to-monitor-non-adherence-disease-states\/","title":{"rendered":"Plan Sponsor Week: Using analytics to monitor non-adherence, disease states"},"content":{"rendered":"<div class=\"alignleft clearfix\">\n<div class=\"wp-caption feature-image alignleft\"> <img decoding=\"async\" loading=\"lazy\" width=\"350\" height=\"263\" src=\"https:\/\/www.benefitscanada.com\/wp-content\/uploads\/2019\/11\/56707217_s-350x263.jpg\" class=\"attachment-feature size-feature wp-post-image\" alt=\"56707217_123RF\" title=\"Plan Sponsor Week: Using analytics to monitor non-adherence, disease states\"> <\/div>\n<\/p><\/div>\n<p class=\"byline\"> <span>Kelsey Rolfe<\/span>&nbsp;|&nbsp;August 28, 2020 <\/p>\n<p>Plan sponsors have to&nbsp;move beyond benefits plan reporting and dig into analytics to better understand&nbsp;medication&nbsp;non-adherence and the top disease states affecting their workforces.<\/p>\n<p><span class=\"s2\">\u201cLeveraging plan-specific data can help answer the fundamental questions needed to manage your benefits program,\u201d&nbsp;<\/span>said Shawn O\u2019Brien, Telus Health\u2019s principal of data enablement and drug, health, dental product roadmaps, during a session&nbsp;at&nbsp;<em>Benefits Canada<\/em>\u2018s 2020 Plan Sponsor Week earlier&nbsp;this month.<\/p>\n<p>While reporting summarizes data from individual sources and can give plan sponsors insight into their past and present drug plan experience, analytics goes further, he said, by&nbsp;providing insights into future trends and drawing connections between separate sources of data to drive strategic decision-making.<\/p>\n<p><strong>Read:&nbsp;<a href=\"https:\/\/www.benefitscanada.com\/news\/mental-health-conditions-specialty-meds-drive-drug-plan-cost-increases-in-2019-report-147866\">Mental-health conditions, specialty meds driving drug plan cost increases in 2019: report<\/a><\/strong><\/p>\n<p>Drug non-adherence is a key area for plan sponsors to watch as it accounts for a large percentage of overall eligible claims cost. Non-adherence is calculated using a medication possession ratio \u2014 the time between&nbsp;when a&nbsp;plan member refills their maintenance medication compared to the number of days\u2019 worth they have.<\/p>\n<p>Four of&nbsp;Telus\u2019 top 10 drug classes by eligible amount were found to have significant non-adherence rates.&nbsp;Depression, which accounted for 5.1 per cent of total eligible claims for&nbsp;the organization\u2019s book of business, had a 23 per cent non-adherence rate. And diabetes, the second-highest drug class, representing 10.6 per cent of total eligible claims, had a 24.8 per cent non-adherence. Two-thirds (65.8 per cent) of asthma patients were non-adherent,&nbsp;along with 16.2 per cent of patients taking cardiovascular and cholesterol medications.<\/p>\n<p><span class=\"s2\">\u201cTaking drugs on time and as prescribed is critical to managing these diseases,\u201d said O\u2019Brien. \u201cOften people that are on anti-depressants may start to feel better and they may skip doses, so there\u2019s certainly reasons for non-compliance. You\u2019ll see asthma has a very, very high non-adherence rate, but it also tends to have a seasonal component, which may explain why we\u2019re not seeing regular fills.\u201d<\/span><\/p>\n<p><strong>Read:&nbsp;<a href=\"https:\/\/www.benefitscanada.com\/news\/drug-adherence-an-increasing-issue-for-plan-members-sponsors-finds-survey-146801\">Drug adherence an increasing issue for plan members, sponsors, finds survey<\/a><\/strong><\/p>\n<p>He also emphasized the need for plan sponsors to monitor their top therapeutic classes. \u201c[That] can shed some light on where the burden of illness lies within your organization. For Telus\u2019 book of business there\u2019s poor adherence across several chronic conditions and those conditions are also present in the top 10 most expensive conditions.\u201d<\/p>\n<p>These therapeutic classes shouldn\u2019t be examined in isolation, he added. For example, a&nbsp;deep dive on the diabetes therapy class showed diabetics taking at least one medication accounted for 4.92 per cent of Telus\u2019 book of business and 17.9 per cent of all claims processed when including syringes, lancets and testing strips.<\/p>\n<p>But upon further examination, claimants with diabetes also contribute heavily to other disease categories. The analysis found 13 co-morbid conditions&nbsp;associated with diabetes claimants. Cholesterol disorders and blood pressure issues&nbsp;were the most common, with more than 200,000&nbsp;diabetic patients also prescribed medications for those two conditions.<\/p>\n<p><span class=\"s2\">\u201cThe point is, you need to look beyond the surface data,\u201d said O\u2019Brien. \u201cYes, the diabetes therapy class is one of the top as far as the overall percentage of paid claims under the benefits program. But when you consider the other conditions, a diabetes patient is responsible for a very high percentage of overall plan costs.\u201d<\/span><\/p>\n<p><strong>All of the&nbsp;2020 Plan Sponsor Week sessions will be available soon on-demand at&nbsp;<a href=\"https:\/\/www.benefitscanada.com\/webinars\">benefitscanada.com\/webinars<\/a>.<\/strong><\/p>\n<p><strong>Read:&nbsp;<a href=\"https:\/\/www.benefitscanada.com\/news\/a-look-at-the-value-of-continuous-glucose-monitoring-131097\">A look at the value of continuous glucose monitoring<\/a><\/strong><\/p>\n<p> <a href=\"https:\/\/www.benefitscanada.com\/news\/plan-sponsor-week-using-analytics-to-monitor-non-adherence-disease-states-149291\">Read the full article at BenefitsCanada.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kelsey Rolfe&nbsp;|&nbsp;August 28, 2020 Plan sponsors have to&nbsp;move beyond benefits plan reporting and dig into analytics to better understand&nbsp;medication&nbsp;non-adherence and the top disease states affecting their workforces. \u201cLeveraging plan-specific data can help answer the&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/19398"}],"collection":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/comments?post=19398"}],"version-history":[{"count":0,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/19398\/revisions"}],"wp:attachment":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/media?parent=19398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/categories?post=19398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/tags?post=19398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}